Remi Barbier, the former — and currently disgraced — CEO of Cassava Sciences, is the Worst Biopharma CEO of 2024.
He’s also the easiest, most obvious selection I’ve ever made for this particular dishonor, something I’ve been doing annually for 17 years.
Barbier had a bad year. Cassava’s Alzheimer’s drug candidate simufilam proved to be nothing more than a placebo in a large clinical trial. The company blew up. He lost his job. He was penalized by the Securities and Exchange Commission. And he remains a defendant in ongoing shareholder and class-action lawsuits.
